No Detail Found!

New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral's in chronic HCV patients

Author(s)
Zahid Yasin Hashmi Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Muhammad Qasim Zia Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Akram Bajwa Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Maqsood Ahmed Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Naveed Anwer Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Mahwish Raza Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Jaffer Bin Baqar Department of Gastroenterology, Liver Center Faisalabad, Faisalabad, Pakistan.
Abstract
Objective: The study aimed to assess the safety profile of Direct Acting Anti-Viral's (DAAs) among patients with chronic Hepatitis C Virus (HCV). Methods: This multicenter, analytical cross-sectional study was conducted in six gastroenterology and Hepatology centers including Liver Center Faisalabad, Allama Iqbal Medical Institute and Liver Center DHQ Hospital Sialkot, Isra Hospital Hyderabad, Allied Hospital Faisalabad and Rehman Medical Institute Peshawar, between May 2018 and May 2019. The data regarding patient demographics, treatment plan and the frequency of Adverse Events (AEs), and their severity was collected using a pre-designed questionnaire and analyzed through SPSS version 20.0. Results: A total of 511 HCV patients were enrolled, with an overall male majority. Around 66.3% patients experienced a total of 419 AEs, out of which 61 events were suspected from DAAs while remaining 317 events were associated with Ribavirin. Pyrexia (24.6%) and fatigue (14.8%) were the most commonly reported AEs among patients receiving DAAs. Factors such as Ribavirin-based treatments and the presence of Cirrhosis were more likely to promote AEs occurrence OR [95%CI] i.e. 5.2(2.3-9.1) and 1.9(1.1-3.1) respectively (p < 0.05). Conclusion: It is concluded from the study results that DAAs have displayed promising outcomes due to the minimal and minor AEs reported.
Publication Details
Page(s) 299-304
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 37, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Chronic hepatitis, Adverse events, Direct-Acting Antivirals
0

Citations

0

Downloads

51

Views